当前位置: 首页 > 期刊 > 《药物与人·相约健康》 > 2014年第5期 > 正文
编号:12713129
老年女性乳腺癌综合治疗的探讨(2)
http://www.100md.com 2014年5月1日 刘安 李云梅 臧涛 王会
第1页

    参见附件。

     [4] Ponzone R,Biglia N,Jncomuzzi Me,et al.Antihormones in prevention and treatment of breast cancer. Ann NYAcad sci,2006,1089:143-158.

    [5] Fisher B,Jeong JH,Bryant J,et al.Treatment of Lymphnode-negative,oestrogen-receptor-positive breast cancer:long-term findings from National Surgical Adjuvant Breast and Bowel project randomised clinical trials. Lancet,2004,364(9437):858-868.

    [6] Howell A,Cuzick J,BaumM,et al.Results of the ATAC(Arimidex,Tamoxifen,Alone or in combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet,2005,365(9453):60-62.

    [7] Coombes RC,Hall E,Gibson LJ,et al.A randomized trial of exemestane afnter two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med,2004,350(11):1081-1092.

    [8] JaKesz R,Jonat W,Gnant M,et al.Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen:combined results of ABCSG trial 8 and ARNO q5 trial. Lancet,2005,366(9484):455-462.

    [9] Goss PE,Ingle JN,Martino S,et al.A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early stage breast cancer. N Engl J Med,2003,349(19):1793-1802.

    [10] Houssami N,Guzict J,Dixon JM.The prevention detection and management of breast cancer. Med J Aust,2006,184(5):230-234.

您现在查看是摘要介绍页,详见PDF附件